comprehensive -WSS

comprehensive

author：knowledge 2025-09-07 11:15:20 - browse：1

Joaquin Duato -- health policy coverage from STAT — Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

“The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： New oral drug delivery patch is modeled after octopus tentacles

explore

focus

WSS

Artificial intelligence use in health care faces greater scrutiny in 2024

Lawsuit highlights wrinkle for disputes over surprise medical bills

Doctors on social media are being harassed and cyberbullied

CDC picks Alphabet's Verily for wasterwater surveillance contract

Experts study whether long Covid risk adds up with each reinfection

What will Novo Nordisk's VC do with its influx of cash?

knowledge

comprehensive

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

Bernie Sanders gets little from pharma CEOs on drug prices

Malaria cases in Florida and Texas: Here’s what you need to know

Congress might make insulin pumps more accessible to the blind

Medicare details structure of new drug price negotiation program

The stability of $0 premiums in Medicare Advantage

In Memoriam: Notable people who died in 2023

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Medical leaders decry Supreme Court decision on affirmative action

Artificial intelligence use in health care faces greater scrutiny in 2024

leisure time

Some top drug companies are starting to take action on climate

Lawsuit highlights wrinkle for disputes over surprise medical bills

Congress might make insulin pumps more accessible to the blind

RSV injection headlines need to be accurate for good uptake

Abbott's new heart device gets FDA advisory panel nod

What we owe ALS patients — and why one company fell short

explore

explore

focus

leisure time